Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.79 |
| ▸ | USP2 | O75604 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | MMP9 | P14780 | 1/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | CA1 | P00915 | 16/20 | 0.42 |
| ▸ | CA2 | P00918 | 16/20 | 0.42 |
| ▸ | CA9 | Q16790 | 15/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA7 | P43166 | 5/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.40 |
| ▸ | CA3 | P07451 | 4/20 | 0.40 |
| ▸ | CA4 | P22748 | 4/20 | 0.40 |
| ▸ | CA6 | P23280 | 4/20 | 0.40 |
| ▸ | CA5A | P35218 | 4/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920792 | 0.97 | TSHR (0.75) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL1109868 | 0.97 | TSHR (0.75) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL922498 | 0.97 | TSHR (0.75) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL290561 | 0.95 | USP2 (0.70) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| Busulfan SCHEMBL4373 | 0.89 | TSHR (1.00) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| Busulfan SCHEMBL4764696 | 0.89 | TSHR (1.00) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL6622075 | 0.88 | USP2 (0.61) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL8592211 | 0.86 | TSHR (0.94) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL4952202 | 0.86 | TSHR (0.94) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| Busulfan SCHEMBL7195165 | 0.86 | TSHR (0.94) | TSHRUSP2ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297114-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9221836-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-29 | — | — | US | disclosed |
| CN-103373985-B | Heterocyclic compounds and their use | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2015-10-28 | — | — | CN | disclosed |
| US-20150191486-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-07-09 | — | — | US | disclosed |
| US-9045436-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| US-8664380-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8466282-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20120264733-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2012-10-18 | — | — | US | disclosed |
| CN-101679324-B | Morpholine derivatives | MITSUBISHI TANABE PHARMA CORP | 2012-10-03 | — | — | CN | disclosed |
| CN-101679324-A | Morpholine derivatives | MITSUBISHI TANABE PHARMA CORP | 2010-03-24 | — | — | CN | disclosed |
| WO-2010024365-A1 | AMIDE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009157527-A1 | BENZOTHIAZOLE CARBOXAMIDES AS FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-12-30 | — | — | WO | disclosed |
| US-7638535-B2 | (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7638535-B2 | (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| WO-2009154300-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-23 | — | — | WO | disclosed |
| US-7635706-B2 | 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| US-7635706-B2 | 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264733-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | TSHR 2597/4885USP2 3546/4885ALDH1A1 156/4885 |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | HTR4, HTR2B, TPH2 | TSHR 722/4885USP2 3647/4885ALDH1A1 854/4885 |
| US-20150191486-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | TSHR 2597/4885USP2 3546/4885ALDH1A1 156/4885 |
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | TSHR 2597/4885USP2 3546/4885ALDH1A1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.